image56
  • Home
  • Technology Platform
  • Pipeline
  • Management
  • Advisors
  • News
  • Contact
image57
  • Home
  • Technology Platform
  • Pipeline
  • Management
  • Advisors
  • News
  • Contact

Esperovax EGRESS RD

Oral Vaccine Delivery

Rapid

Inexpensive

Inexpensive

Our vaccine candidates can be produced in less than 2 weeks and billions of doses can be manufactured in less than a month

Inexpensive

Inexpensive

Inexpensive

Our vaccines don't require costly purification and cold storage so each dose can be produced for pennies

Safe

Inexpensive

Safe

We use common baker's yeast, something that people eat and drink everyday. With a modest change, we have transformed it into a life saving edible therapeutic

Oral Delivery

In-Situ Vaccine Producion

In-Situ, Virus-Like Particle (VLP) Delivery

Esperovax has developed a proprietary method for bioengineering probiotic yeast to deliver continuous and high concentrations of vaccine antigen in the gut. These antigens are delivered in the form of enveloped virus like particles (eVLPs) right to the lymphoid tissue (payers patches) of the gut mucosa, inducing strong immune protection. 

EVLP, RVLP, or self-amplifying AVLPs

 Our oral delivery platform uses two different methods to deliver antigens, either through proteins produced as part of the VLP (a standard EVLP), or capturing mRNA inside the particle. The RNA can be mRNA (RVLP), or a self-amplifying RNA (AVLP).

Esperovax Egress-RD Platform

Copyright © 2018 Esperovax - All Rights Reserved


Powered by GoDaddy